Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension.

Gupta V, Gupta N, Shaik IH, Mehvar R, McMurtry IF, Oka M, Nozik-Grayck E, Komatsu M, Ahsan F.

J Control Release. 2013 Apr 28;167(2):189-99. doi: 10.1016/j.jconrel.2013.01.011. Epub 2013 Jan 23.

2.

Peptide-coated liposomal fasudil enhances site specific vasodilation in pulmonary arterial hypertension.

Nahar K, Absar S, Gupta N, Kotamraju VR, McMurtry IF, Oka M, Komatsu M, Nozik-Grayck E, Ahsan F.

Mol Pharm. 2014 Dec 1;11(12):4374-84. doi: 10.1021/mp500456k. Epub 2014 Nov 4.

3.

Cocktail of Superoxide Dismutase and Fasudil Encapsulated in Targeted Liposomes Slows PAH Progression at a Reduced Dosing Frequency.

Gupta N, Rashid J, Nozik-Grayck E, McMurtry IF, Stenmark KR, Ahsan F.

Mol Pharm. 2017 Mar 6;14(3):830-841. doi: 10.1021/acs.molpharmaceut.6b01061. Epub 2017 Feb 17.

PMID:
28165252
4.

Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension.

Fujita H, Fukumoto Y, Saji K, Sugimura K, Demachi J, Nawata J, Shimokawa H.

Heart Vessels. 2010 Mar;25(2):144-9. doi: 10.1007/s00380-009-1176-8. Epub 2010 Mar 26.

PMID:
20339976
5.

Fasudil and SOD packaged in peptide-studded-liposomes: Properties, pharmacokinetics and ex-vivo targeting to isolated perfused rat lungs.

Gupta N, Al-Saikhan FI, Patel B, Rashid J, Ahsan F.

Int J Pharm. 2015 Jul 5;488(1-2):33-43. doi: 10.1016/j.ijpharm.2015.04.031. Epub 2015 Apr 15.

6.
7.

Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats.

Jiang BH, Tawara S, Abe K, Takaki A, Fukumoto Y, Shimokawa H.

J Cardiovasc Pharmacol. 2007 Feb;49(2):85-9.

PMID:
17312448
8.

The beneficial impact of fasudil and sildenafil on monocrotaline-induced pulmonary hypertension in rats: a hemodynamic and biochemical study.

Jasińska-Stroschein M, Owczarek J, Łuczak A, Orszulak-Michalak D.

Pharmacology. 2013;91(3-4):178-84. doi: 10.1159/000346921. Epub 2013 Feb 21.

PMID:
23428587
9.

Liposomal Aerosols of Nitric Oxide (NO) Donor as a Long-Acting Substitute for the Ultra-Short-Acting Inhaled NO in the Treatment of PAH.

Nahar K, Rashid J, Absar S, Al-Saikhan FI, Ahsan F.

Pharm Res. 2016 Jul;33(7):1696-710. doi: 10.1007/s11095-016-1911-7. Epub 2016 Apr 5.

10.

Peptide-micelle hybrids containing fasudil for targeted delivery to the pulmonary arteries and arterioles to treat pulmonary arterial hypertension.

Gupta N, Ibrahim HM, Ahsan F.

J Pharm Sci. 2014 Nov;103(11):3743-3753. doi: 10.1002/jps.24193. Epub 2014 Sep 29.

11.

Nano-engineered erythrocyte ghosts as inhalational carriers for delivery of fasudil: preparation and characterization.

Gupta N, Patel B, Ahsan F.

Pharm Res. 2014 Jun;31(6):1553-65. doi: 10.1007/s11095-013-1261-7. Epub 2014 Jan 22.

12.

Starch-coated magnetic liposomes as an inhalable carrier for accumulation of fasudil in the pulmonary vasculature.

Nahar K, Absar S, Patel B, Ahsan F.

Int J Pharm. 2014 Apr 10;464(1-2):185-95. doi: 10.1016/j.ijpharm.2014.01.007. Epub 2014 Jan 21.

13.

Evaluation of clinical efficacy of fasudil for the treatment of pulmonary arterial hypertension.

Raja SG.

Recent Pat Cardiovasc Drug Discov. 2012 Aug;7(2):100-4. Review.

PMID:
22670803
14.

Encapsulation of an antivasospastic drug, fasudil, into liposomes, and in vitro stability of the fasudil-loaded liposomes.

Ishida T, Takanashi Y, Doi H, Yamamoto I, Kiwada H.

Int J Pharm. 2002 Jan 31;232(1-2):59-67.

PMID:
11790490
15.

Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.

Mouchaers KT, Schalij I, de Boer MA, Postmus PE, van Hinsbergh VW, van Nieuw Amerongen GP, Vonk Noordegraaf A, van der Laarse WJ.

Eur Respir J. 2010 Oct;36(4):800-7. doi: 10.1183/09031936.00130209. Epub 2010 Mar 29.

16.

Role of Rho-kinase signaling and endothelial dysfunction in modulating blood flow distribution in pulmonary hypertension.

Schwenke DO, Pearson JT, Sonobe T, Ishibashi-Ueda H, Shimouchi A, Kangawa K, Umetani K, Shirai M.

J Appl Physiol (1985). 2011 Apr;110(4):901-8. doi: 10.1152/japplphysiol.01318.2010. Epub 2011 Jan 6.

PMID:
21212241
17.

Analysis of pulmonary vasodilator responses to the Rho-kinase inhibitor fasudil in the anesthetized rat.

Badejo AM Jr, Dhaliwal JS, Casey DB, Gallen TB, Greco AJ, Kadowitz PJ.

Am J Physiol Lung Cell Mol Physiol. 2008 Nov;295(5):L828-36. doi: 10.1152/ajplung.00042.2008. Epub 2008 Aug 8.

PMID:
18689606
18.

Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension.

Jasińska-Stroschein M, Owczarek J, Plichta P, Orszulak-Michalak D.

Pharmacology. 2014;93(3-4):145-50. doi: 10.1159/000360182. Epub 2014 Mar 18.

PMID:
24662671
19.

Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension.

Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S, Abe K, Takeshita A, Shimokawa H.

Heart. 2005 Mar;91(3):391-2. No abstract available.

20.

[Fasudil reverses monocrotaline-induced pulmonary hypertension in rats].

Jiang H, Guan RJ, Wang HY.

Zhonghua Xin Xue Guan Bing Za Zhi. 2013 Mar;41(3):239-44. Chinese.

PMID:
23879951

Supplemental Content

Support Center